Stock Buybacks (Quarterly) Chart

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 -3.00M
March 31, 2026 0.00
December 31, 2025 -2.192M
September 30, 2025 -0.002M
June 30, 2025 -83.65M
March 31, 2025 -0.157M
December 31, 2024 -3.186M
September 30, 2024 -4.174M
June 30, 2024 -384.94M
March 31, 2024 0.058M
December 31, 2023 -383.91M
September 30, 2023 -0.442M
June 30, 2023 -3.069M
March 31, 2023 -0.75M
December 31, 2022 -2.001M
September 30, 2022 -1.074M
June 30, 2022 -5.983M
March 31, 2022 -1.755M
December 31, 2021 -85.87M
September 30, 2021 -7.674M
June 30, 2021 -12.74M
March 31, 2021 -12.76M
December 31, 2020 -489.80M
September 30, 2020 -19.19M
June 30, 2020 -35.87M
Date Value
March 31, 2020 -55.65M
December 31, 2019 -1.209M
September 30, 2019 -0.904M
June 30, 2019 -9.342M
March 31, 2019 -353.62M
December 31, 2018 -12.24M
September 30, 2018 -25.02M
June 30, 2018 -13.17M
March 31, 2018 -286.42M
December 31, 2017 -69.38M
September 30, 2017 -1.333M
June 30, 2017 -1.526M
March 31, 2017 -68.97M
December 31, 2016 -74.94M
September 30, 2016 -63.45M
June 30, 2016 0.025M
March 31, 2016 -0.314M
December 31, 2015 -0.887M
September 30, 2015 -288.65M
June 30, 2015 -2.595M
March 31, 2015 -175.44M
December 31, 2014 -2.697M
September 30, 2014 -60.51M
June 30, 2014 -0.01M
March 31, 2014 -126.10M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
Ionis Pharmaceuticals, Inc. -20.26M
AbbVie, Inc. 9.00M
Krystal Biotech, Inc. -15.16M
BridgeBio Pharma, Inc. -900.22M
Alnylam Pharmaceuticals, Inc. -15.46M